share_log

B of A Securities Maintains Underperform on Integra Lifesciences, Lowers Price Target to $18

B of A Securities Maintains Underperform on Integra Lifesciences, Lowers Price Target to $18

B of A證券維持對英特格拉生命科學的跑輸市場評級,將目標股價下調至18美元
Benzinga ·  2024/10/08 01:12  · 評級/大行評級

B of A Securities analyst Craig Bijou maintains Integra Lifesciences (NASDAQ:IART) with a Underperform and lowers the price target from $26 to $18.

美國銀行證券分析師克雷格·比喬維維持英特格拉生命科學(納斯達克:IART)的賣出評級,並將目標股價從26美元降至18美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論